References on the Administration of AIDS or HIV Treatments Using ALZET® Osmotic Pumps
(Note: Please see CYTO Bibliography for additional cytokines)
1. Aprotinin
P5676 Ito,H., Hayashi,I., Izumi,T., Majima,M. Bradykinin inhibits development of myocardial infarction through B-2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats. British Journal of Pharmacology 2003; 138(-1-):225-233. >>> FR-190997; aprotinin; SBTI; Saline; water; HCl; IV (vena cava, cervical vein); Rat; 2001D; 24 hours; Controls received mp w/ vehicle; cardiovascular; FR-190997 (a nonpeptide mimic of bradykinin beta 2 agonist) was infused into the vena cava; aprotinin infused into the cervical vein; SBTI&aprotinin are plasma kallikrein inhibitors from soybeans.
P4270 Frautschy,S.A., Horn,D.L., Sigel,J.J., Harris-White,M.E., Mendoza,J.J., Yang,F., Saido,T.C., Cole,G.M. Protease inhibitor coinfusion with amyloid beta-protein results in enhanced deposition and toxicity in rat brain. Journal of Neuroscience 1998/10/15; 18(-20-):8311-8321. >>> Amyloid protein, beta; Aprotinin; Leupeptin;; HEPES;; CSF/CNS;; rat; 2004;; 4 weeks; controls received mp w/ vehicle; peptides; ALZET brain infusion kit used; beta-amyloid protein infused alone, or concomitantly with aprotinin or leupeptin; enzyme inhibitors.
P3324 Yosipiv,I.V., El-Dahr,S.S. Developmental regulation of ACE gene expression by endogenous kinins and angiotensin II. Am.J.Physiol.(Renal Fluid Electrolyte Physiol.38) 1995; 269(--):F172-F179. >>> Aprotinin; Hoe 140; Losartan; SC; rat; 5,7 days; controls received mp w/saline.
P3035 Morin,N.J., Frau,A., Nonclercq,D., Toubeau,G., Zanen,J., Heuson-Stiennon,J.-A., Bergeron,M.G., Beauchamp,D., Laurent,G. Potentiation of gentamicin nephrotoxicity in the rat by infusion of aprotinin. Exp.Molecular Path. 1994; 60(--):197-213. >>> Aprotinin; IV; rat; 2ML1; 8 days; controls received mp with saline; immunology; toxicology.
P3268 Majima,M., Yoshida,O., Mihara,H., Muto,T., Mizogami,S., Kuribayashi,Y., Katorim,M., Oh-ishi,S. High sensitivity to salt in kininogen-deficient brown Norway Katholiek rats. Hypertension 1993; 22(--):705-714. >>> Kininogen, bovine; Hoe 140; Aprotinin; Saline; SC; rat; 2001; 7 days; controls received mp w/saline.
P1987 Ivy,G.O. Protease inhibitors as a model for NCL disease, with special emphasis on the infantile and adult forms. Am.J.Med.Genet. 1992; 42(--):555-560. >>> E-64C; Aprotinin; Chloroquine; Leupeptin; CSF/CNS; rat; 2002; 2 weeks; no comment posted.
P1964 Majima,M., Katori,M., Hanazuka,M., Mizogami,S., Nakano,T., Nakao,Y., Mikami,R., Uryu,H., Okamura,R., Mohsin,S.S.J., Oh-ishi,S. Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension 1991; 17(-6-):806-813. >>> Aprotinin; Saline; SC; rat; 2001; 7 days; no comment posted.
P1673 Pakzad,R. Influence of the trypsin inhibitors aprotinin (Trasylol) and TLCK, administered locally by osmotic minipumps, on the gelatinolytic activity of acrosin and the transport of spermatozoa in the female reproductive tract of rabbits. Z.Mikrosk.-Anat.Forsch. 1989; 103(-6-):957-966. >>> Lysine chloromethyl ketone, N-a-tosyl-L-; Aprotinin; intrauterine; rabbit; 6 days; German with English summary (p. 957); trypsin inhibitors; tissue perfusion (uterus).
2. Azidothymidine
P2211 Tarantal,A.F., Spanggord,R.J., Hendrickx,A.G. Pre and postnatal treatment of the rhesus macaque (Macaca mulatta) with azidothymidine: I. fetal studies. Pediatr.Aids HIV Infection: Fetus to Adolescent 1994; 5(-1-):10-19. >>> Azidothymidine; Sodium hydroxide; SC; monkey (pregnant); 2ML4; 28 days; controls received mp w/vehicle; functionality of mp verified by plasma levels of AZT; teratology; AZT is azidothymidine, also known as zidovudine; multiple pumps per animal (3-4); "Circulating levels of AZT remained constant during the course of treatment and were achieved by the first (24 hr.) sample (p. 11)..
P2093 Sinet,M., Harcouet,L., Desforges,B., Colin,J.N., Farinotti,R., Pocidalo,J.J. Efficacy of continuous zidovudine infusion at early stages of retroviral infection in mice. J.Acquir.Immune Defic.Syndr. 1992; 5(--):577-582. >>> Azidothymidine; Propylene glycol; Water; SC; mice; 2001; 5 days; functionality of mp verified by plasma AZT levels; comparison of b.i.d. s.c. injections vs. mp; good methods; also called zidovudine; pK; half-life (p.577); continuous infusion significantly more effective than bolus injection.
P1928 Bilello,J.A., MacAuley,C., Fredrickson,T.N., Bell,M.M., McKissick,C., Shapiro,S.G., Personette,R., Eiseman,J.L. Use of a neonatal murine retrovirus model to evaluate the long-term efficacy and toxicity of antiviral agents. Ann.N.Y.Acad.Sci. 1990; 616(--):238-251. >>> Azidothymidine; mice (pregnant); 2001; 21 days; pumps replaced after each week to achieve 3 weeks duration; immunology; teratology; oral delivery of AZT resulted in highly variable plasma levels.
P1644 Gallo,J.M., Clark,L.N., Rubino,J.T. Pump delivery of azidothymidine: potential for constant concentrations and improved brain delivery. J.Controlled Release 1989; 9(--):249-253. >>> Azidothymidine; IA (carotid); rat; 2001; 3-7 days; Dose-response; blood levels; comparison of IV injections vs. mp; good methods; antiviral; alkaline pH of 11 increased solubility and stability of AZT.
3. Clindamycin
P1074 Astry,C.L., Nelson,S., Karam,G.H., Summer,W.R. Interactions of clindamycin with antibacterial defenses of the lung. Am.Rev.Respir.Dis. 1987; 135(--):1015-1019. >>> Clindamycin HCl; Penicillin G; Sodium hydroxide; Water; SC; mice; 72 hours; Pump model not stated; controls received mp w/water; dose-response; mp primed overnight in PSB; 2 doses of agent infused; agent infused separately; antibiotic.
P0953 Hollenbach,S.J., DeGuzman,L.R., Bellamy,R.F. Early administration of methylprednisolone promotes survival in rats with intra-abdominal sepsis. Circ.Shock 1986; 20(-2-):161-168. >>> Clindamycin; Methylprednisolone; Gentamicin; Naloxone; Saline; SC; rat; 2001; 7 days; controls received mp w/saline; toxicology; multiple pumps per animal (3); comparison of bolus injections vs. mp infusion; antibiotic.
4. IL-2
P7460 Roychowdhury,S., Blaser,B.W., Freud,A.G., Katz,K., Bhatt,D., Ferketich,A.K., Bergdall,V., Kusewitt,D., Baiocchi,R.A., Caligiuri,M.A. IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease. Blood 2005; 106(-7-):2433-2435. >>> Interleukin-15, recomb. human; interleukin-2, recomb. human; PBS; albumin, human; SC; Mice (SCID); 1007D; 10 days; Controls received mp w/ vehicle; immunology; animal info (female, CB17, hu-PBL-SCID, 8-12 weeks old).
P6765 Neal,Z.C., Yang,J.C., Rakhmilevich,A.L., Buhtoiarov,I.N., Lum,H.E., Imboden,M., Hank,J.A., Lode,H.N., Reisfeld,R.A., Gillies,S.D., Sondel,P.M. Enhanced activity of Hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clinical Cancer Research 2004; 10(-14-):4839-4847. >>> Interleukin-2, recomb. human; SC; Mice; 2001; 7 days; Controls received mp w/ PBS; no stress (see pg.4841); cancer (neuroblastoma); peptides.
P6450 Jean,W.C., Spellman,S.R., Wallenfriedman,M.A., Flores,C.T., Kurtz,B.P., Hall,W.A., Low,W.C. Effects of combined granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2, and interleukin-12 based immunotherapy against intracranial glioma in the rat. Journal of Neuro-oncology 2004; 66(-1-2-):39-49. >>> Colony-stimulating factor, GM; interleukin-2; interleukin-12; SC; Rat; 2004; 4 weeks; Cancer (gliosarcoma); GM-CSF was infused alone or with cytokines.
R0190 Anisman,H., Kokkinidis,L., Merali,Z. Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes. BRAIN BEHAVIOR AND IMMUNITY 2002; 16(-5-):544-556. >>> Interleukin-2; Mice; 7 days; Controls received mp w/ saline; peptides; examined anhedonic effects of IL-2.
P4872 Margenthaler,J.A., Tu,F., Otomo,N., Shimizu,Y., Yu,S., Flye,M.W. Immunogenicity of Ld+ transgenic mouse hearts. Surgery 2001; 130(--):217-224. >>> Interleukin-2; mice; 1007D; 7 days; controls received no IL-2 treatment; immunology; peptides.
P4815 Hautmann,S., Huland,E., Wullbrand,A., Friedrich,M., Huland,H. Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumps.. Anticancer Research 2000; 20(--):4495-4498. >>> Interleukin-2;; Albumin, human;; SC; Peritumoral (orthotopic);; rat;; 2002;; ; Controls received mp w/ vehicle; functionality of mp verified by in vitro assay; no stress (see p. 4496); good methods pumps weighed p. 4496; cancer; immunology; peptides; rats had a prostatic adenocarcinoma tumor implanted; Albumin vehicle was 20% concentration; SC&peritumoral orthotopic implantation; Note: these pumps were left in for 28 days;.
P4630 Ueno,M. Lymphokine-activated killer cells induced in vivo in mice showing IL-2 toxicity have cytoplasmic granules containing perforin and its hemolytic activity.. Immunopharmacology 1998; 39(--):75-82. >>> Interleukin-2;; SC;; mice;; 2001;; 8 days;; immunology; peptides; recomb. human IL-2 was used..
P4557 Schirrmacher,V, Müerköster,S, Umansky,V. Antagonistic effects of systemic interleukin 2 on immune Tcell-mediated graft-versus-leukemia reactivity.. Clinical Cancer Research 1998/11; 4(--):2635-2645. >>> Interleukin-2, recomb. human;; PEG;; mice;; 2002;; 12 days;; controls received mp w/vehicle; comparison of IP injections of PEG-IL-2 vs. IL-2 infusion via mp; cancer; immunology; peptides;.
P4112 Hautmann,S., Huland,E., Wulbrand,A., Friedrich,M., Huland,H. Treatment of metastatic hormone refractory adenocarcinoma of the prostate (mat ly ly) with micro-osmotic interleukin-2 pump in male copenhagen rats. Eur.Urol. 1998; 34(--):265-266. >>> Interleukin-2; Albumin; intratumoral; rat; no duration posted; controls received mp w/albumin; tissue perfusion (intratumoral); cancer; immunology; peptides.
P4089 Johansson,S., Landstrom,M., Hellstrand,K., Henriksson,R. The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. Br.J.Cancer 1998; 77(-8-):1213-1219. >>> Interleukin-2; SC; rat; 2002; 6 weeks; pumps replaced every 2 weeks; cancer; immunology; peptides.
P3731 Galbiati,F., Rogge,L., Guery,J.-C., Smiroldo,S., Adorini,L. Regulation of the IL-12 receptor B2 subunit by soluble antigen and IL-12 in vivo. Eur.J.Immunol. 1998; 28(--):209-220. >>> Interleukin-12; Interleukin-2; Lysozyme, hen egg white; Ovalbumin; Interferon-gamma; PBS; Albumin, mouse serum; SC; mice; 2001; 9 days; controls received mp w/ PBS; comparison of ip injections vs. mp; immunology; peptides; agents infused singly or in combination in the same pump; recomb. human IL-2 used; recomb. mouse IFN-gamma used.
P6325 Isobe,M, Suzuki,J., Yamazaki,S., Yazaki,Y, Horie,S., Okubo,Y., Maemura,K., Yazaki,Y, Sekiguchi,M. Regulation by Differential Development of Th1 and Th2 Cells in Peripheral Tolerance to Cardiac Allograft Induced by Blocking ICAM-1/LFA-1 Adhesion. Circulation 1997; 96(--):2247-2253. >>> Interleukin-2, recomb.; Culture medium, RPMI 1640; fetal calf serum; Mice; 1007D; 7 days; Cardiovascular.
P4466 Fehniger,T.A, Carson,W.E, Mrózek,E, Caligiuri,M.A. Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.. Blood 1997/11/1; 90(-9-):3647-3653. >>> Interleukin-2; PBS; Serum, syngeneic mouse; SC; Mice; 8 weeks; Controls received mp w/vehicle; functionality of mp verified by plasma levels; long-term study, pump replaced every 10 days; immunology; peptides.
P4572 Junghans,R.P, Waldmann,T.A. Metabolism of Tac (IL2Ra): Physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.. J.Exp.Med. 1996/4; 183(--):1587-1602. >>> Interleukin-2 receptor-alpha;; 131I tracer;; SC;; mice;; 7 days;; functionality of mp verified by plasma levels; comparison of IP injections vs. mp; IL-2 receptor-alpha also called CD25 or Tac; pumps were used to infuse radiolabeled receptor;.
P4095 Hanisch,U.-K., Neuhaus,J., Quirion,R., Kettenmann,H. Neurotoxicity induced by interleukin-2: involvement of infiltrating immune cells. Synapse 1996; 24(--):104-114. >>> Interleukin-2; CSF/CNS; rat; 1007D; 2002; 7,14 days; controls received mp w/heat-inactivated IL-2 or IL-3; functionality of mp verified by emptied drug reservoir; good methods (pp. 105-106); ALZET brain infusion kit used; no stress - "icv delivery of solutions at a rate of 0.5 ul/h was shown previously not to cause any tissue damage due to volume overload." (p. 106); recomb. human IL-2 used.
P3594 Kuroda,K., Yagi,J., Imanishi,K., Yan,X.-J., Li,X-Y., Fujimaki,W., Kato,H., Miyoshi-Akiyama,T., Kumazawa,Y., Abe,H., Uchiyama,T. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial superantigen. J.Immunol. 1996; 157(--):1422-1431. >>> Interleukin-2; SC; mice; 2001; no duration posted; immunology; peptides; penicillin g given prophylactically; recomb. human IL-2 used.
P2849 Patselas,T., Thomas,F., Areneda,D., Marchman,W. Role of natural killer and killer cells in concordant xenograft rejection. Transplant.Proc. 1995; 27(-1-):262-263. >>> Interleukin-2; mice; 3 days; no comment posted.
P2942 Schneider,G.B., Relfson,M. Effects of interleukin-2 on bone resorption and natural immunity in osteopetrotic (ia) rats. Lymphokine Cytokine Res. 1994; 13(-6-):335-341. >>> Interleukin-2; rat; 2002; 14 days; controls received mp with vehicle; immunology; peptides; normal and incisors absent osteopetrotic rats used; recomb. human IL-2 used.
P2749 Hanisch,U.-K., Rowe,W., Sharma,S., Meaney,M.J., Quirion,R. Hypothalamic-pituitary-adrenal activity during chronic central administration of interleukin-2. Endocrinology 1994; 135(-6-):2465-2472. >>> Interleukin-2; Interleukin-2, inactivated; PBS; Albumin, bovine serum; CSF/CNS; rat; 2002; 14 days; controls received mp w/ inactivated IL-2 or only cannula implantation; functionality of mp verified by opening pump body after infusion; no stress (see pg. 2466); stability verified for up to 7 days at 37C in cat CSF w/o any decrease in biological activity; peptides; ALZET brain infusion kit used; minimal tissue damage confined to cannula tract; recomb. human IL-2 used.
P2510 Ishizu,H., Bove,K.E., Ziegler,M.M., Arya,G. Immune-mediated regression of 'metastatic' neuroblastoma in the liver. J.Pediatr.Surg. 1994; 29(-2-):155-160. >>> Interleukin-2; Saline; Serum; intrasplenic; mice; 14 days; tissue perfusion (spleen); dose-response (graph, p.156); cancer; immunology; peptides.
P2292 Basse,P.H., Goldfarb,R.H., Herberman,R.B., Hokland,M.E. Accumulation of adoptively transferred A-NK cells in murine metastases: kinetics and role of interleukin-2. In Vivo 1994; 8(--):17-24. >>> Interleukin-2-PEG; Interleukin-2; IP; mice; no duration posted; cancer; half-life prolonged by complexing IL-2 to polyethylene glycol.
P3103 Vallera,D.A., Taylor,P.A., Aukerman,S.L., Blazar,B.R. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2. Cancer Res. 1993; 53(--):4273-4280. >>> Colony-stimulating factor, M; Interleukin-2; Colony-stimulating factor, G; SC; mice; no duration posted; controls received mp with PBS; cancer; immunology; peptides; M-CSF + IL-2 given concomitantly provided best antitumor protection; recomb. IL-2 used; human G-CSF used.
P2305 Claessen,A.M.E., Bloemena,E., Bril,H., Meijer,C.J.L.M., Scheper,R.J. Locoregional administration of etoposide, but not of interleukin 2, facilitates active specific immunization in guinea pigs with advanced carcinoma. Cancer Res. 1992; 52(--):2440-2446. >>> Interleukin-2; Etoposide; SC; guinea-pig; 2001; 2002; 1 and 2 weeks; comparison of local injections vs. mp (table, p. 2442); cancer.
P2076 Henriksson,R., Widmark,A., Bergh,A., Damber,J.E. Interleukin-2-induced growth inhibition of prostatic adenocarcinoma (Dunning R3327) in rats. Urol.Res. 1992; 20(--):189-191. >>> Interleukin-2; SC; rat; 2002; 4 weeks; pumps replaced once after 14 days; no stress (see pg. 190); cancer; immunology; peptides.
P1999 Denis,M. Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis. J.Leukoc.Biol. 1991; 50(--):495-501. >>> Interferon-gamma, inactivated; Tumor necrosis factor-a; Interferon-gamma; Interleukin-2; Interleukin-2, inactivated; Tumor necrosis factor-a, inactivated; IP; mice; 2002; no duration posted; peptides.
P1837 Lorberboum-Galski,H., Lafyatis,R., Case,J.P., Fitzgerald,D., Wilder,R.L., Pastan,I. Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion. Int.J.Immunopharmac. 1991; 13(-2/3-):305-315. >>> Interleukin-2, PE40; NAD; IP; rat; 2001; no duration posted; functionality of mp verified by serum levels of IL-2-PE40; comparison of of bid ip injections vs. mp; no stress (see pg. 314); stability achieved for 6 days by adding NAD (p. 308); multiple pumps per animal (2); half-life of 1-2 hours when given ip.
R0089 Amkraut,A., Eckenhoff,J.B., Nichols,K. Osmotic delivery of peptides and macromolecules. Adv.Drug Delivery Review 1990; 4(--):255-276. >>> Atrial natriuretic factor; Cholecystokinin; Colony-stimulating factor, G.; Glucagon; Insulin; Interleukin-2; Interleukin-3; Melatonin; Nerve growth factor; Neurotensin; Prolactin; Theophylline; CSF/CNS; IA (femoral); intrasplenic; IP; SC; no duration posted; peptides; ALZA-authored, review of peptide delivery issues and applications; tissue perfusion (spleen).
P1621 Nickerson,S.C., Baker,P.A., Trinidad,P. Local immunostimulation of the bovine mammary gland with interleukin-2. J.Dairy Sci. 1989; 72(--):1764-1773. >>> Interleukin-2; Water; mammary gland; cattle; 2 weeks; tissue perfusion; stress/adverse reaction some local mechanical damage (see pg. 1772); peptides; bovine IL-2 used.
P1160 Naito,K., Pellis,N.R., Kahan,B.D. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide. Cancer Res. 1988; 48(--):101-108. >>> Interleukin-2; IP; IV; mice; 1702; 2001; 2002; 2ML2; 10 days; mp connected to catheter; half-life; 2 doses infused; IL-2 infused to potentiate effects of TSTA/CY inject.; comparison of bolus inject. vs. inject. vs. mp infusion; tissue perfusion (spleen); cancer/immunology; peptides; human IL-2 used.
P1144 Kalland,T. Physiology of Natural Killer Cells. J.Immunol. 1987; 139(-11-):3671-3675. >>> Interleukin-2; Interleukin-3; SC; mice; 2001; 8, 16 days; controls received mp w/ unspecified vehicle or sham op; 2 experiments using mp, IL-2 infused for 8 days, IL-3 infused for 16 days; comparison of agents effects; pump replaced after eight days; peptides.
P1069 Niederkorn,J.Y. Exogenous recombinant interleukin-2 abrogates anterior-chamber-associated immune deviation. Transplantation 1987; 43(-4-):523-528. >>> Interleukin-2; Saline; SC; mice; 2001; 9-10 days; controls received mp w/saline; half-life; agents inf. sep.; mice inoculated w/P815 tumor cells; mice pretreated w/syclophamide as a means of reducing serum-borne IL-2 inhibitor; pump replaced after 6 days; peptides; recomb. human&mouse IL-2 used.
P0424 Talmadge,J.E., Phillips,H., Schindler,J., Tribble,H., Pennington,R. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res. 1987; 47(--):5725-5732. >>> Interleukin-2; Acetic acid; IP; mice; 3, 5-14 days; pump model not stated; controls rec'd mp w/ acetic acid; half-life; 7 day pump used for 3 day, 14 day pump used for 5-14 days; 2 doses of agent infused; solubility of rH IL 2 was a rate limiting factor; cancer/immunology; peptides; recomb. human IL-2 used.
P0872 Nishimura,T., Uchiyama,Y., Yagi,H., Hashimoto,Y. Administration of slowly released recombinant interleukin 2. Augmentation of the efficacy of adoptive immunotherapy with lymphokine-activated killer (LAK) cells. J.Immunol.Methods 1986; 91(--):21-27. >>> Interleukin-2; Saline; IP; SC; mice; 2001; 96 hours; controls rec'd mp w/saline; half-life data for IL-2; comparison of single injection vs. mp infusion; cancer; peptides; recomb. human IL-2 used.
P0846 Barbul,A., Knud-Hansen,J., Wasserkrug,H.L., Efron,G. Interleukin 2 enhances wound healing in rats. J.Surg.Res. 1986; 40(--):315-319. >>> Interleukin-2; IP; rat; 2ML1; 7 days; controls received mp w/vehicle; wound healing; functionality of mp verified upon removal; peptides; recomb. human IL-2 used.
P0786 Nishimura,T., Togashi,Y., Goto,M., Yagi,H., Uchiyama,Y., Hashimoto,Y. Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2. Cancer Immunol.Immunother. 1986; 21(-1-):12-18. >>> Interleukin-2; mice; 2001; 26 days; mp replaced periodically; mp implanted near tumor (sc?); mp infusion of II2w/ administration of cyclophosphamide and adoptive chemoimmunotherapy; cancer; immunotherapy; peptides; recomb. human IL-2 used.
P0550 Chang,A.E., Hyatt,C.L., Rosenberg,S.A. Systemic administration of recombinant human interleukin-2 in mice. J.Biol.Response Mod. 1984; 3(-5-):561-572. >>> Interleukin-2; Hank's solution; IP; SC; mice; 6 days; comparison of daily ip or sc injec. vs. ip or sc mp infusion; stability of IL-2 at 37C for 7 days verified; mp functionality verified; injec. of IL-2 gel tested; immunotherapy; previous mp exp. done in vitro in tissue culture; cancer; peptides; recomb. human IL-2 used.
P0549 Merluzzi,V.J., Last-Barney,K. Expansion of murine cytotoxic precursors in vitro and in vivo by purified interleukin-2. J.Biol.Response Mod. 1984; 3(-5-):468-474. >>> Interleukin-2; SC (inguinal lymph node); mice; 1 week; comparison of agents effects; immunotherapy; pump portal end adjacent to lymph node; cancer chemotherapy; peptides; tissue perfusion; rat&human IL-2 used.
P0551 Merluzzi,V.J., Welte,K., Savage,D.M., Last-Barney,K., Mertelsmann,R. Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. J.Immunol. 1983; 131(-2-):806-809. >>> Interleukin-2; Culture medium, RPMI; SC (inguinal lymph node); mice; 1 week; immunotherapy; no stress p. 807 - preliminary control tests - mp had no effect on immune response; mp implant near inguinal lymph node; mp functionality checked in vitro; cancer chemotherapy; tissue perfusion; human IL-2 used.
5. Interferons
P8261 Si,Y., Ciccone,S., Yang,F.C., Yuan,J., Zeng,D., Chen,S., van de Vrugt,H.J., Critser,J., Arwert,F., Haneline,L.S., Clapp,D.W. Continuous in vivo infusion of interferon-gamma (IFN-gamma) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice. Blood 2006; 108(-13-):4283-4287. >>> Interferon-gamma, mouse; PBS; SC; Mice; 1007D; 7 days; Controls received mp w/ vehicle; no stress (see pg. 4286); immunology; peptides; animal info (C57BL/6).
P7725 Birk,R.Z., Rubinstein,M. IFN-alpha induces apoptosis of adipose tissue cells. Biochemical and Biophysical Research Communications 2006; 345(-2-):669-674. >>> Interferon-a A/D, recomb. human; Saline; SC; Mice; 8 days; Controls received mp w/ vehicle; animal info (C57BL/6, diet-induced obese).
P7447 Kang,W.Q., Rathinavelu,S., Samuelson,L.C., Merchant,J.L. Interferon gamma induction of gastric mucous neck cell hypertrophy. LABORATORY INVESTIGATION 2005; 85(-5-):702-715. >>> Interferon-gamma, recomb. mouse; IP; Mice; 1002; 14 days; Controls received PBS; animal info (c57BL/6).
P7184 Mathian,A., Weinberg,A., Gallegos,M., Banchereau,J., Koutouzov,S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand black x New Zealand White)F1 but not in BALB/c mice1. Journal of Immunology 2005; 174(-5-):2499-2506. >>> Interferon, mouse; PBS; BSA; SC; Mice; 1002; 8-10 weeks; Controls received mp w/ vehicle; long-term study; pumps replaced every 2 weeks; immunology.
P7132 Brooling,J.T., Campbell,J.S., Mitchell,C., Yeoh,G.C., Fausto,N. Differential regulation of rodent hepatocyte and oval cell proliferation by interferon gamma. Hepatology 2005; 41(-4-):906-915. >>> Interferon-gamma, recomb. mouse; SC; Mice; 4-6 days; Controls received mp w/ saline; replacement therapy (hepatectomy).
P7042 Li,X.X., Yang,Y.Z., Yuan,J., Hong,P., Freie,B., Orazi,A., Haneline,L.S., Clapp,D.W. Continuous in vivo infusion of interferon-gamma (IFN-gamma) preferentially reduces myeloid progenitor numbers and enhances engraftment of syngeneic wild-type cells in Fancc(-/-) mice. Blood 2004; 104(-4-):1204-1209. >>> Interferon-gamma, murine; PBS; SC; Mice; 1007D; 7 days; Controls received mp w/ vehicle; dose-response (fig. 7); no stress (pg. 1209); stress/adverse reaction: (see pg. 1205) "modest though not significant rise in peripheral white blood cell count" (pg. 1205); "IFN-gamma was overall well tolerated by both WT and Fancc -/- mice." (pg. 1208); hematology.
P6764 Frewert,S., Stockhammer,F., Warschewske,G., Zenclussen,A.C., Rupprecht,S., Volk,H.D., Woiciechowsky,C. Intratumoral infusion of interleukin-1 beta and interferon-gamma; induces tumor invasion with macrophages and lymphocytes in a rat glioma model. Neuroscience Letters 2004; 364(-3-):145-148. >>> Interleukin-1, beta recomb. rat; Interferon-gamma, recomb. rat; Saline, physiological; albumin, human serum; CSF/CNS (intratumoral); Rat; 1003D; 48 hours; Controls received mp w/ vehicle; tissue perfusion (tumor); cancer (glioma).
P6048 Zavros,Y., Rathinavelu,S., Kao,J.Y., Todisco,A., Del Valle,J., Weinstock,J.V., Low,M.J., Merchant,J.L. Treatment of Helicobacter gastritis with IL-4 requires somatostatin. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2003; 100(-22-):12944-12949. >>> Interleukin-4; interferon-gamma; PBS; IP; Mice; 1007D; 7 days; Controls received mp w/ vehicle; comparison of IP injections vs. IP mp.
P6142 Koyanagi,S., Ohdo,S. Alteration of intrinsic biological rhythms during interferon treatment and its possible mechanism. MOLECULAR PHARMACOLOGY 2002; 62(-6-):1393-1399. >>> Interferon-alpha; Saline, sterile; SC; Mice; 2001; 7 days; Controls received mp w/ vehicle; immunology; peptides.
P5102 Skovseth,D.K., Yamanaka,T., Brandtzaeg,P., Butcher,E.C., Haraldsen,G. Vascular morphogenesis and differentiation after adoptive transfer of human endothelial cells to immunodeficient mice. American Journal of Pathology 2002; 160(-5-):1629-1637. >>> Interferon-gamma; Abdominal wall; mice; 2004; ; tissue perfusion (abdominal wall); immunology; peptides; pump implanted SC, catheter tube perfused matrigel plug in abdominal wall..
P4675 Jander,S, Schroetter,M, Fischer,J, Stoll,G. Differential regulation of microglial keratan sulfate immunoreactivity by proinflammatory cytokines and colony-stimulating factors.. Glia 2000; 30(--):401-410. >>> Interferon-gamma; Tumor necrosis factor-a;; PBS, sterile;; CSF/CNS;; rat;; 1007D;; 6 days;; Controls received mp w/ vehicle; immunology; peptides; ALZET brain infusion kit used; proinflammatory cytokines;.
P4551 Nedelec,B, Dodd,C.M, Scott,P.G, Ghahary,A., Tredget,E.E. Effect of interferon-alpha 2b on guinea pig wound closure and the expression of cytoskeletal proteins in vivo.. Wound Repair and Regeneration 1998/6/1; 6(--):202-212. >>> Interferon-a2b; Saline, sterile; IP; Guinea-pig; 2ML4; 7, 14, 21 days; Controls received mp w/vehicle; wound healing study.
P3986 Henke,P.K., Bergamini,T.M., Watson,A.L., Brittian,K.R., Powell,D.W., Peyton,J.C. Bacterial products primarily mediate fibroblast inhibition in biomaterial infection. J.Surg.Res. 1998; 74(--):17-22. >>> Antibody, anti-interferon gamma; Antibody, indomethacin; Antibody, anti-TNFa; Antibody, interleukin 1 alpha; PBS, sterile; ETOH; Indomethacin; SC; mice; 1007D; 7 days; immunology; pump implanted next to Dacron graft; peptides.
P3731 Galbiati,F., Rogge,L., Guery,J.-C., Smiroldo,S., Adorini,L. Regulation of the IL-12 receptor B2 subunit by soluble antigen and IL-12 in vivo. Eur.J.Immunol. 1998; 28(--):209-220. >>> Interleukin-12; Interleukin-2; Lysozyme, hen egg white; Ovalbumin; Interferon-gamma; PBS; Albumin, mouse serum; SC; mice; 2001; 9 days; controls received mp w/ PBS; comparison of ip injections vs. mp; immunology; peptides; agents infused singly or in combination in the same pump; recomb. human IL-2 used; recomb. mouse IFN-gamma used.
P3567 Tsuji-Takayama,K., Harashima,A., Tahata,H., Izumi,N., Nishida,Y., Namba,M., Okuda,Y., Ohta,T., Kurimoto,M. IFN-gamma in combination with IL-3 accelerates platelet recovery in mice with 5-fluorouracil-induced marrow aplasia. J.Interferon and Cytokine Res. 1996; 16(--):447-451. >>> Interferon-gamma; Interleukin-3; Albumin, mouse serum; PBS; SC; mice; 1007D; 7 days; controls received mp w/ vehicle; stability verified after 7 day storage; immunology; peptides; cytokines given singly and together.
P3501 Siesjo,P., Visse,E., Sjogren,H.O. Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J.Immunol. 1996; 19(-5-):334-345. >>> Interferon-gamma; SC; CSF/CNS; rat; 14 days; cancer; immunology; peptides; ALZET brain infusion kit used.
P4477 Voest,E.E, Kenyon,B.M, O'Reilly,M.S, Truitt,G, D'Amato,R.J, Folkman,J. Inhibition of angiogenesis in vivo by interleukin 12.. Journal of the National Cancer Institute 1995; 87(-8-):581-586. >>> Interferon-gamma; Saline; IM; Mice (scid); 2002; ; Controls received mp w/ saline; functionality of mp verified by checking residual volume; comparison of bolus invections vs. mp; cancer; immunology; angiogenesis inhibitor; recomb. murine interferon-gamma used; "... in comparison with bolus injections, continuous intraperitoneal infusion of IFN gamma achieved enhanced inhibition of angiogenesis ..." (p. 585).
P2935 Rapp,J., Dallah,C.N., Schulz-Key,H. Parenteral administration of cytokines and drugs in rodent filariasis via osmotic pumps. Parasite 1994; 1(-1S-):35-37. >>> Interferon-gamma; SC; mice; 2002; 14 days; controls received mp with PBS or were untreated; no stress (see pg. 37); immunology; "implantation of osmotic pumps is a suitable method for the application of short lived substances like IFN-gamma or other cytokines."; incision heals within three days and animals show no signs of discomfort, making pumps a useful alternative to repeated injections especially for rodents..."; recomb. mouse IFN-gamma used.
P2677 Drath,D.B., Do,C., Burd,T., Hong,L.L. Activation of a distinct subpopulation of pulmonary macrophages following exposure to biological response modifiers. Immunol.Invest. 1994; 23(-2-):115-127. >>> Interferon-gamma; S-MDP, free; S-MDP, liposome-encapsulated; SC; rat; 7 days; comparison of bolus tracheal injections, iv administration and mp; immunology; peptides; IFN-gamma and S-MDP were most effective when delivered either intravenously or via osmotic minipump infusion; S-MDP is lipophilic N-acetylmuramyl-6-0-stearoyl-alanyl-D-isoglutamine; recomb. mouse IFN-gamma used.
P2625 Wiranowska,M., Prockop,L.D., Naidu,A.K., Saporta,S., Kori,S., Kulkarni,A.P. Interferon entry through the blood-brain barrier in glioma and its effect on lipoxygenase activity. Anticancer Res. 1994; 14(--):1121-1126. >>> Interferon-a/B, mouse; Interferon-gamma; SC; mice; 3 days; cancer; peptides; recomb. mouse IFN-gamma used.
P2533 Rockey,D.C., Chung,J.J. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J.Invest.Med. 1994; 42(-4-):660-670. >>> Interferon-gamma; PBS; Albumin, bovine serum; IP; rat; 2ML4; no duration posted; controls received mp w/ vehicle; immunology; peptides; rat IFN-gamma used.
P3104 Unemori,E.N., Beck,L.S., Lee,W.P., Xu,Y., Siegel,M., Keller,G., Liggitt,H.D., Bauer,E.A., Amento,E.P. Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis. J.Invest.Dermatol. 1993; 101(--):280-285. >>> Relaxin; Interferon-gamma; PBS; SC; rat; mice; 2002; no duration posted; controls received mp with vehicle; immunology; multiple pumps per animal (1-2) for relaxin delivery; polyvinyl alcohol sponges implanted subcutaneously in rats for fibrotic infiltration; intentional capsule formation in mice analyzed.
P3004 Flynn,J.L., Chan,J., Triebold,K.J., Dalton,D.K., Stewart,T.A., Bloom,B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J.Exp.Med. 1993; 178(--):2249-2254. >>> Interferon-gamma; PBS; SC; mice; no duration posted; controls received mp w/ PBS or could endogenously produce IFN; replacement therapy (genetic inability to produce IFN-gamma); comparison of im injections vs. mp; circulating half-life of IFN-gamma in mice is about 1 hour; continuous delivery of IFN-gamma prolonged survival longer than did IFN injections (12 vs. 4 days longer than controls); mouse IFN-gamma used.
P2948 Curfs,J.H.A.J., van der Meide,P.H., Billiau,A., Meuwissen,J.H.E.Th., Eling,W.M.C. Plasmodium berghei: recombinant interferon-y and the development of parasitemia and cerebral lesions in malaria-infected mice. Exp.Parasitology 1993; 77(--):212-223. >>> Interferon-gamma; Saline, isotonic; IP; mice; mice (nude); 2002; no duration posted; controls were untreated, or treated but uninfected; ". . .daily injection of a bolus of 105 units of IFN-gamma is not lethal, whereas even a lower daily total dose of 2.5 x 104 units of IFN-gamma administered by continuous release is lethally toxic."; only continuous delivery was able to prevent development of cerebral malaria; comparison of ip injections vs. mp; recomb. rat IFN-gamma.
P2494 Rosiello,R.A., Merrill,W.W., Rockwell,S., Carter,D., Cooper Jr,J.A.D., Care,S., Amento,E.P. Radiation pneumonitis: bronchoalveolar lavage assessment and modulation by a recombinant cytokine. Am.Rev.Respir.Dis. 1993; 148(--):1671-1676. >>> Interferon-gamma; SC; rat; 26 days; peptides; oncology.
P2301 Kuhn,J.A., Wong,J.Y.C., Beatty,B.G., Esteban,J.M., Williams,L.E., Beatty,J.D. Gamma-interferon enhancement of carcinoembryonic antigen expression in human colon carcinoma xenografts. J.Immunother. 1992; 11(--):257-266. >>> Interferon-gamma; Albumin, bovine serum; PBS; SC; mice; 1007D; 3-7 days; functionality of mp verified by residual amounts; dose-response (text p. 259, graph p. 260); comparison of ip injections vs. infusion; cancer; immunology; peptides; biological activity of residual in pump diminished 15% by day 4, 25% by day 6 (p. 262); recomb. human IFN-gamma used.
P2121 Wiranowska,M., Gonzalvo,A.A., Saporta,S., Gonzalez,O.R., Prockop,L.D. Evaluation of blood-brain barrier permeability and the effect of interferon in mouse glioma model. J.Neurooncology 1992; 14(--):225-236. >>> Interferon-a/B, mouse; SC; mice; 1003D; 3 days; cancer; homologous mouse IFN-a/B used.
P1999 Denis,M. Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis. J.Leukoc.Biol. 1991; 50(--):495-501. >>> Interferon-gamma, inactivated; Tumor necrosis factor-a; Interferon-gamma; Interleukin-2; Interleukin-2, inactivated; Tumor necrosis factor-a, inactivated; IP; mice; 2002; no duration posted; peptides.
P1845 Denis,M. Recombinant murine beta interferon enhances resistance of mice to systemic mycobacterium avium infection. Infect.Immun. 1991; 59(-5-):1857-1859. >>> Interferon-beta; mice; 2002; no duration posted; controls received pumps with heat-inactivated cytokines; peptides.
P1947 Newton,G.R., Martinod,S., Hansen,P.J., Thatcher,W.W., Siegenthaler,B., Gerber,C., Voirol,M.-J. Effect of bovine interferon on acute changes in body temperature and serum progesterone concentration in heifers. J.Dairy Sci. 1990; 73(--):3439-3448. >>> Interferon-a1; cattle; 2ML1; 5 days; peptides; serum IFN-a levels (p. 3445).
P1718 Murray,H.W. Effect of continuous administration of interferon-y in experimental visceral leishmaniasis. J.Infect.Dis. 1990; 161(--):992-994. >>> Stibogluconate, sodium; Interferon-gamma; Albumin, bovine serum; Saline; SC; mice; 2002; 1 week; comparison of ip injections vs. mp; immunology; some mice received 2 pumps.
P1918 Granstein,R.D., Deak,M.R., Jacques,S.L., Margolis,R.J., Flotte,T.J., Whitaker,D., Long,F.H., Amento,E.P. The systemic administration of gamma interferon inhibits collagen synthesis and acute inflammation in a murine skin wound model. J.Invest.Dermatol. 1989; 93(-1-):18-27. >>> Interferon-gamma; PBS; Serum, mouse; IP; SC; mice; 2002; 14 days; peptides; wound healing.
P1293 Guadagni,F., Schlom,J., Pothen,S., Pestka,S., Greiner,J.W. Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon. Cancer Immunol.Immunother. 1988; 26(--):222-230. >>> Interferon-a, recomb. human; Saline; SC; mice (nude); 2001; 5-13 days; dose-response (graph); half life; comparison of i.m. injections vs. mp infusion; functionality of mp verified by plasma levels; cancer/immunology; peptides.
P0987 Granstein,R.D., Murphy,G.F., Margolis,R.J., Byrne,M.H., Amento,E.P. Gamma-interferon inhibits collagen synthesis in vivo in the mouse. J.Clin.Invest. 1987; 79(-4-):1254-1258. >>> Interferon-gamma; PBS; Serum, mouse; SC; mice; 2002; 7-14 days; 2002, 7-14 days; controls received mp w/vehicle; peptides; immunology; stress/adverse reaction (fibrous tissue formation which was used to study effects of gamma-interferon).
P0957 Drath,D.B. Modulation of pulmonary macrophage superoxide release and tumoricidal activity following activation by biological response modifiers. Immunopharmacology 1986; 12(-2-):117-126. >>> Interferon-gamma; Liposomes; SC; rat; 2001; 7 days; controls received mp w/empty liposomes; liposome encapsulated agent and free agent; comparison of iv injections vs. mp infusion; cancer/immunology; peptides.
P0504 Heston,W.D.W., Fleischmann,J., Tackett,R.E., Ratliff,T.L. Effects of a-difluoromethylornithine and recombinant interferon-a2 on the growth of a human renal cell adenocarcinoma xenograft in nude mice. Cancer Res. 1984; 44(--):3220-3225. >>> Interferon-a2, recomb. human; SC; mice (nude); 2002; 4 weeks; pump replaced after 2 weeks; immunotherapy; controls received unidentified vehicle in mp; peptides; cancer; recomb. human IF-a2 used.
6. Interleukin-2
P6765 Neal,Z.C., Yang,J.C., Rakhmilevich,A.L., Buhtoiarov,I.N., Lum,H.E., Imboden,M., Hank,J.A., Lode,H.N., Reisfeld,R.A., Gillies,S.D., Sondel,P.M. Enhanced activity of Hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clinical Cancer Research 2004; 10(-14-):4839-4847. >>> Interleukin-2, recomb. human; SC; Mice; 2001; 7 days; Controls received mp w/ PBS; no stress (see pg.4841); cancer (neuroblastoma); peptides.
R0190 Anisman,H., Kokkinidis,L., Merali,Z. Further evidence for the depressive effects of cytokines: Anhedonia and neurochemical changes. BRAIN BEHAVIOR AND IMMUNITY 2002; 16(-5-):544-556. >>> Interleukin-2; Mice; 7 days; Controls received mp w/ saline; peptides; examined anhedonic effects of IL-2.
P4872 Margenthaler,J.A., Tu,F., Otomo,N., Shimizu,Y., Yu,S., Flye,M.W. Immunogenicity of Ld+ transgenic mouse hearts. Surgery 2001; 130(--):217-224. >>> Interleukin-2; mice; 1007D; 7 days; controls received no IL-2 treatment; immunology; peptides.
P4815 Hautmann,S., Huland,E., Wullbrand,A., Friedrich,M., Huland,H. Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumps.. Anticancer Research 2000; 20(--):4495-4498. >>> Interleukin-2;; Albumin, human;; SC; Peritumoral (orthotopic);; rat;; 2002;; ; Controls received mp w/ vehicle; functionality of mp verified by in vitro assay; no stress (see p. 4496); good methods pumps weighed p. 4496; cancer; immunology; peptides; rats had a prostatic adenocarcinoma tumor implanted; Albumin vehicle was 20% concentration; SC&peritumoral orthotopic implantation; Note: these pumps were left in for 28 days;.
P4630 Ueno,M. Lymphokine-activated killer cells induced in vivo in mice showing IL-2 toxicity have cytoplasmic granules containing perforin and its hemolytic activity.. Immunopharmacology 1998; 39(--):75-82. >>> Interleukin-2;; SC;; mice;; 2001;; 8 days;; immunology; peptides; recomb. human IL-2 was used..
P4557 Schirrmacher,V, Müerköster,S, Umansky,V. Antagonistic effects of systemic interleukin 2 on immune Tcell-mediated graft-versus-leukemia reactivity.. Clinical Cancer Research 1998/11; 4(--):2635-2645. >>> Interleukin-2, recomb. human;; PEG;; mice;; 2002;; 12 days;; controls received mp w/vehicle; comparison of IP injections of PEG-IL-2 vs. IL-2 infusion via mp; cancer; immunology; peptides;.
P4112 Hautmann,S., Huland,E., Wulbrand,A., Friedrich,M., Huland,H. Treatment of metastatic hormone refractory adenocarcinoma of the prostate (mat ly ly) with micro-osmotic interleukin-2 pump in male copenhagen rats. Eur.Urol. 1998; 34(--):265-266. >>> Interleukin-2; Albumin; intratumoral; rat; no duration posted; controls received mp w/albumin; tissue perfusion (intratumoral); cancer; immunology; peptides.
P4089 Johansson,S., Landstrom,M., Hellstrand,K., Henriksson,R. The response of Dunning R3327 prostatic adenocarcinoma to IL-2, histamine and radiation. Br.J.Cancer 1998; 77(-8-):1213-1219. >>> Interleukin-2; SC; rat; 2002; 6 weeks; pumps replaced every 2 weeks; cancer; immunology; peptides.
P6325 Isobe,M, Suzuki,J., Yamazaki,S., Yazaki,Y, Horie,S., Okubo,Y., Maemura,K., Yazaki,Y, Sekiguchi,M. Regulation by Differential Development of Th1 and Th2 Cells in Peripheral Tolerance to Cardiac Allograft Induced by Blocking ICAM-1/LFA-1 Adhesion. Circulation 1997; 96(--):2247-2253. >>> Interleukin-2, recomb.; Culture medium, RPMI 1640; fetal calf serum; Mice; 1007D; 7 days; Cardiovascular.
P4466 Fehniger,T.A, Carson,W.E, Mrózek,E, Caligiuri,M.A. Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.. Blood 1997/11/1; 90(-9-):3647-3653. >>> Interleukin-2; PBS; Serum, syngeneic mouse; SC; Mice; 8 weeks; Controls received mp w/vehicle; functionality of mp verified by plasma levels; long-term study, pump replaced every 10 days; immunology; peptides.
P4572 Junghans,R.P, Waldmann,T.A. Metabolism of Tac (IL2Ra): Physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.. J.Exp.Med. 1996/4; 183(--):1587-1602. >>> Interleukin-2 receptor-alpha;; 131I tracer;; SC;; mice;; 7 days;; functionality of mp verified by plasma levels; comparison of IP injections vs. mp; IL-2 receptor-alpha also called CD25 or Tac; pumps were used to infuse radiolabeled receptor;.
P4095 Hanisch,U.-K., Neuhaus,J., Quirion,R., Kettenmann,H. Neurotoxicity induced by interleukin-2: involvement of infiltrating immune cells. Synapse 1996; 24(--):104-114. >>> Interleukin-2; CSF/CNS; rat; 1007D; 2002; 7,14 days; controls received mp w/heat-inactivated IL-2 or IL-3; functionality of mp verified by emptied drug reservoir; good methods (pp. 105-106); ALZET brain infusion kit used; no stress - "icv delivery of solutions at a rate of 0.5 ul/h was shown previously not to cause any tissue damage due to volume overload." (p. 106); recomb. human IL-2 used.
P3594 Kuroda,K., Yagi,J., Imanishi,K., Yan,X.-J., Li,X-Y., Fujimaki,W., Kato,H., Miyoshi-Akiyama,T., Kumazawa,Y., Abe,H., Uchiyama,T. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial superantigen. J.Immunol. 1996; 157(--):1422-1431. >>> Interleukin-2; SC; mice; 2001; no duration posted; immunology; peptides; penicillin g given prophylactically; recomb. human IL-2 used.
P2849 Patselas,T., Thomas,F., Areneda,D., Marchman,W. Role of natural killer and killer cells in concordant xenograft rejection. Transplant.Proc. 1995; 27(-1-):262-263. >>> Interleukin-2; mice; 3 days; no comment posted.
P2942 Schneider,G.B., Relfson,M. Effects of interleukin-2 on bone resorption and natural immunity in osteopetrotic (ia) rats. Lymphokine Cytokine Res. 1994; 13(-6-):335-341. >>> Interleukin-2; rat; 2002; 14 days; controls received mp with vehicle; immunology; peptides; normal and incisors absent osteopetrotic rats used; recomb. human IL-2 used.
P2749 Hanisch,U.-K., Rowe,W., Sharma,S., Meaney,M.J., Quirion,R. Hypothalamic-pituitary-adrenal activity during chronic central administration of interleukin-2. Endocrinology 1994; 135(-6-):2465-2472. >>> Interleukin-2; Interleukin-2, inactivated; PBS; Albumin, bovine serum; CSF/CNS; rat; 2002; 14 days; controls received mp w/ inactivated IL-2 or only cannula implantation; functionality of mp verified by opening pump body after infusion; no stress (see pg. 2466); stability verified for up to 7 days at 37C in cat CSF w/o any decrease in biological activity; peptides; ALZET brain infusion kit used; minimal tissue damage confined to cannula tract; recomb. human IL-2 used.
P2510 Ishizu,H., Bove,K.E., Ziegler,M.M., Arya,G. Immune-mediated regression of 'metastatic' neuroblastoma in the liver. J.Pediatr.Surg. 1994; 29(-2-):155-160. >>> Interleukin-2; Saline; Serum; intrasplenic; mice; 14 days; tissue perfusion (spleen); dose-response (graph, p.156); cancer; immunology; peptides.
P2292 Basse,P.H., Goldfarb,R.H., Herberman,R.B., Hokland,M.E. Accumulation of adoptively transferred A-NK cells in murine metastases: kinetics and role of interleukin-2. In Vivo 1994; 8(--):17-24. >>> Interleukin-2-PEG; Interleukin-2; IP; mice; no duration posted; cancer; half-life prolonged by complexing IL-2 to polyethylene glycol.
P3103 Vallera,D.A., Taylor,P.A., Aukerman,S.L., Blazar,B.R. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2. Cancer Res. 1993; 53(--):4273-4280. >>> Colony-stimulating factor, M; Interleukin-2; Colony-stimulating factor, G; SC; mice; no duration posted; controls received mp with PBS; cancer; immunology; peptides; M-CSF + IL-2 given concomitantly provided best antitumor protection; recomb. IL-2 used; human G-CSF used.
P2305 Claessen,A.M.E., Bloemena,E., Bril,H., Meijer,C.J.L.M., Scheper,R.J. Locoregional administration of etoposide, but not of interleukin 2, facilitates active specific immunization in guinea pigs with advanced carcinoma. Cancer Res. 1992; 52(--):2440-2446. >>> Interleukin-2; Etoposide; SC; guinea-pig; 2001; 2002; 1 and 2 weeks; comparison of local injections vs. mp (table, p. 2442); cancer.
P2076 Henriksson,R., Widmark,A., Bergh,A., Damber,J.E. Interleukin-2-induced growth inhibition of prostatic adenocarcinoma (Dunning R3327) in rats. Urol.Res. 1992; 20(--):189-191. >>> Interleukin-2; SC; rat; 2002; 4 weeks; pumps replaced once after 14 days; no stress (see pg. 190); cancer; immunology; peptides.
P1999 Denis,M. Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis. J.Leukoc.Biol. 1991; 50(--):495-501. >>> Interferon-gamma, inactivated; Tumor necrosis factor-a; Interferon-gamma; Interleukin-2; Interleukin-2, inactivated; Tumor necrosis factor-a, inactivated; IP; mice; 2002; no duration posted; peptides.
P1837 Lorberboum-Galski,H., Lafyatis,R., Case,J.P., Fitzgerald,D., Wilder,R.L., Pastan,I. Administration of IL-2-PE40 via osmotic pumps prevents adjuvant induced arthritis in rats. Improved therapeutic index of IL-2-PE40 administered by continuous infusion. Int.J.Immunopharmac. 1991; 13(-2/3-):305-315. >>> Interleukin-2, PE40; NAD; IP; rat; 2001; no duration posted; functionality of mp verified by serum levels of IL-2-PE40; comparison of of bid ip injections vs. mp; no stress (see pg. 314); stability achieved for 6 days by adding NAD (p. 308); multiple pumps per animal (2); half-life of 1-2 hours when given ip.
R0089 Amkraut,A., Eckenhoff,J.B., Nichols,K. Osmotic delivery of peptides and macromolecules. Adv.Drug Delivery Review 1990; 4(--):255-276. >>> Atrial natriuretic factor; Cholecystokinin; Colony-stimulating factor, G.; Glucagon; Insulin; Interleukin-2; Interleukin-3; Melatonin; Nerve growth factor; Neurotensin; Prolactin; Theophylline; CSF/CNS; IA (femoral); intrasplenic; IP; SC; no duration posted; peptides; ALZA-authored, review of peptide delivery issues and applications; tissue perfusion (spleen).
P1621 Nickerson,S.C., Baker,P.A., Trinidad,P. Local immunostimulation of the bovine mammary gland with interleukin-2. J.Dairy Sci. 1989; 72(--):1764-1773. >>> Interleukin-2; Water; mammary gland; cattle; 2 weeks; tissue perfusion; stress/adverse reaction some local mechanical damage (see pg. 1772); peptides; bovine IL-2 used.
P1160 Naito,K., Pellis,N.R., Kahan,B.D. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide. Cancer Res. 1988; 48(--):101-108. >>> Interleukin-2; IP; IV; mice; 1702; 2001; 2002; 2ML2; 10 days; mp connected to catheter; half-life; 2 doses infused; IL-2 infused to potentiate effects of TSTA/CY inject.; comparison of bolus inject. vs. inject. vs. mp infusion; tissue perfusion (spleen); cancer/immunology; peptides; human IL-2 used.
P1144 Kalland,T. Physiology of Natural Killer Cells. J.Immunol. 1987; 139(-11-):3671-3675. >>> Interleukin-2; Interleukin-3; SC; mice; 2001; 8, 16 days; controls received mp w/ unspecified vehicle or sham op; 2 experiments using mp, IL-2 infused for 8 days, IL-3 infused for 16 days; comparison of agents effects; pump replaced after eight days; peptides.
P1069 Niederkorn,J.Y. Exogenous recombinant interleukin-2 abrogates anterior-chamber-associated immune deviation. Transplantation 1987; 43(-4-):523-528. >>> Interleukin-2; Saline; SC; mice; 2001; 9-10 days; controls received mp w/saline; half-life; agents inf. sep.; mice inoculated w/P815 tumor cells; mice pretreated w/syclophamide as a means of reducing serum-borne IL-2 inhibitor; pump replaced after 6 days; peptides; recomb. human&mouse IL-2 used.
P0424 Talmadge,J.E., Phillips,H., Schindler,J., Tribble,H., Pennington,R. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res. 1987; 47(--):5725-5732. >>> Interleukin-2; Acetic acid; IP; mice; 3, 5-14 days; pump model not stated; controls rec'd mp w/ acetic acid; half-life; 7 day pump used for 3 day, 14 day pump used for 5-14 days; 2 doses of agent infused; solubility of rH IL 2 was a rate limiting factor; cancer/immunology; peptides; recomb. human IL-2 used.
P0872 Nishimura,T., Uchiyama,Y., Yagi,H., Hashimoto,Y. Administration of slowly released recombinant interleukin 2. Augmentation of the efficacy of adoptive immunotherapy with lymphokine-activated killer (LAK) cells. J.Immunol.Methods 1986; 91(--):21-27. >>> Interleukin-2; Saline; IP; SC; mice; 2001; 96 hours; controls rec'd mp w/saline; half-life data for IL-2; comparison of single injection vs. mp infusion; cancer; peptides; recomb. human IL-2 used.
P0846 Barbul,A., Knud-Hansen,J., Wasserkrug,H.L., Efron,G. Interleukin 2 enhances wound healing in rats. J.Surg.Res. 1986; 40(--):315-319. >>> Interleukin-2; IP; rat; 2ML1; 7 days; controls received mp w/vehicle; wound healing; functionality of mp verified upon removal; peptides; recomb. human IL-2 used.
P0786 Nishimura,T., Togashi,Y., Goto,M., Yagi,H., Uchiyama,Y., Hashimoto,Y. Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2. Cancer Immunol.Immunother. 1986; 21(-1-):12-18. >>> Interleukin-2; mice; 2001; 26 days; mp replaced periodically; mp implanted near tumor (sc?); mp infusion of II2w/ administration of cyclophosphamide and adoptive chemoimmunotherapy; cancer; immunotherapy; peptides; recomb. human IL-2 used.
P0550 Chang,A.E., Hyatt,C.L., Rosenberg,S.A. Systemic administration of recombinant human interleukin-2 in mice. J.Biol.Response Mod. 1984; 3(-5-):561-572. >>> Interleukin-2; Hank's solution; IP; SC; mice; 6 days; comparison of daily ip or sc injec. vs. ip or sc mp infusion; stability of IL-2 at 37C for 7 days verified; mp functionality verified; injec. of IL-2 gel tested; immunotherapy; previous mp exp. done in vitro in tissue culture; cancer; peptides; recomb. human IL-2 used.
P0549 Merluzzi,V.J., Last-Barney,K. Expansion of murine cytotoxic precursors in vitro and in vivo by purified interleukin-2. J.Biol.Response Mod. 1984; 3(-5-):468-474. >>> Interleukin-2; SC (inguinal lymph node); mice; 1 week; comparison of agents effects; immunotherapy; pump portal end adjacent to lymph node; cancer chemotherapy; peptides; tissue perfusion; rat&human IL-2 used.
P0551 Merluzzi,V.J., Welte,K., Savage,D.M., Last-Barney,K., Mertelsmann,R. Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2. J.Immunol. 1983; 131(-2-):806-809. >>> Interleukin-2; Culture medium, RPMI; SC (inguinal lymph node); mice; 1 week; immunotherapy; no stress p. 807 - preliminary control tests - mp had no effect on immune response; mp implant near inguinal lymph node; mp functionality checked in vitro; cancer chemotherapy; tissue perfusion; human IL-2 used.
7. Muramyl Dipeptide
P0040 Kierszenbaum,F., Ferraresi,R.W. Enhancement of host resistance against Trypanosoma cruzi infection by the immunoregulatory agent muramyl dipeptide. Infect.Immun. 1979; 25(-1-):273-278. >>> Muramyl dipeptide; Saline; SC; mice; 7 days; comparison of ip injec. vs sc infusion; immunotherapy; peptides.
8. PMEA
P1963 Lee,J.S., Mullaney,S., Bronson,R., Sharpe,A.H., Jaenisch,R., Balzarini,J., De Clercq,E., Ruprecht,R.M. Transplacental antiretroviral therapy with 9-(2-phosphonylmethoxyethyl)adenine is embryotoxic in transgenic mice. J.Acquir.Immune Defic.Syndr. 1991; 4(--):833-838. >>> PMEA; Mice; no duration posted; comparison of ip injections vs. mp; teratology; antiviral agent.
9. R-95288
P3720 Agatsuma,T., Abe,K., Furukawa,H., Koga,R., Koizumi,M., Hotoda,H., Kaneko,M. Protection of hu-PBL-SCID/beige mice from HIV-1 infection by a 6-mer modified oligonucleotide, R-95288. Antiviral Res. 1997; 34(--):121-130. >>> R-95288; Saline; IP; SC; mice (SCID); 2002; no duration posted; controls received mp w/saline; antisense; mice were transplanted w/human peripheral blood leukocytes; R-95288 protects human chimeric mice against HIV-1 infection; AIDS.
10. SID 791
P3587 Datema,R., Rabin,L., Hincenbergs,M., Moreno,M.B., Warren,S., Linquist,V., Rosenwirth,B., Seifert,E., McCune,J.M. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob.Agents Chemother. 1996; 40(-3-):750-754. >>> SID 791; Saline, sterile; SC; mice (SCID); mice; 2002; no duration posted; functionality of mp verified by plasma levels; dose-response; comparison of sc injections vs. mp; immunology; SID 791 is a bicyclam which inhibits HIV replication in vivo; human fetal liver&thymus transplanted into SCID mice.
Looking for references? We can help!
ALZET will perform a custom bibliography search for you! ALZET pumps have been used to deliver hundreds of different compounds, including proteins and peptides, in a myriad of different experimental applications. We have recently updated our database, which now contains over 11,000 references that can help you guide your research project!
Researchers are saying ...
“This study showed that pump-controlled delivery of a Nogo-A-specific antibody (7B12) initiated 24 hours after experimental stroke promoted improvement of long-term neurologic outcome in normotensive and SHR rats.” Wiessner et al, J Cereb Blood Flow Metab 2003;23(2):162.
